Nine cystic fibrosis patients homozygous for the CFTR nonsense mutation R1162X have mild or moderate lung disease.
AUTOR(ES)
Gasparini, P
RESUMO
The clinical course of nine cystic fibrosis patients homozygous for the CF gene nonsense mutation R1162X was investigated. Since this mutation should lead to an interruption in the synthesis of the cystic fibrosis transmembrane regulator (CFTR) protein, a severe clinical course was expected. All patients showed pancreatic insufficiency, while the course of the lung disease was mild to moderate. These results suggest that this form of truncated CFTR protein, still containing the regulatory region, the first ATP binding domain, and both transmembrane domains, could be partially working in the lung tissues.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1016062Documentos Relacionados
- A cystic fibrosis patient homozygous for the nonsense mutation R553X.
- Nonsense mutation R1162X of the cystic fibrosis transmembrane conductance regulator gene does not reduce messenger RNA expression in nasal epithelial tissue.
- Mild pulmonary disease in a cystic fibrosis child homozygous for R553X.
- Severe cystic fibrosis in a child homozygous for the G542 nonsense mutation in the CFTR gene.
- A cystic fibrosis patient who is homozygous for the G85E mutation has very mild disease.